AbbVie Lutikizumab Hits Primary Endpoint in Phase 3 Hidradenitis Suppurativa Trial

AbbVie's lutikizumab met its primary endpoint in a phase 3 clinical trial for hidradenitis suppurativa, a chronic and debilitating inflammatory skin disease, the company announced on October 22. The result marks a significant milestone for the dual interleukin-1 alpha and beta inhibitor, which AbbVie had advanced into phase 3 following promising phase 2 data showing higher response rates than placebo in patients who had previously failed anti-TNF therapy. The phase 3 trial used a more stringent primary endpoint of HiSCR75, a measure requiring at least a 75 percent reduction in lesion count, and enrolled a broader patient population including more treatment-naive patients. Shares of AbbVie rose approximately 1.4 percent in premarket trading on the news.

Separately, BioNTech announced it is advancing a phase 3 clinical trial of its anti-cancer antibody pumitamig in combination with Gilead's TROP2-directed antibody-drug conjugate sacituzumab govitecan for patients with triple-negative breast cancer, one of the most aggressive and hardest-to-treat forms of the disease. Bio-Thera also disclosed it will present phase 2 data for its ADC candidate BAT8008 in combination with the PD-1 inhibitor BAT1308 at the ESMO 2026 congress, adding to a busy stretch of oncology pipeline updates across the sector.